Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 3, 2014, Pages 175-180

  Balandin Moreno, B ^a   Fernandez Simon I ^a   Pintado Garcia V ^b   Sanchez Romero I ^a   Isidoro Fernandez B ^a   Romera Ortega, M A ^a   Alcantara Carmona S ^a   Perez Redondo M ^a   Galdos Anuncibay, P ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Carbapenemase producing Enterobacteriaceae; Critically ill; Klebsiella pneumoniae; Multidrug resistant Gram negative bacteria; Tigecycline

Indexed keywords

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES;

EID: 84894356236     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.861608     Document Type: Article

References (30)

1. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-6.
2. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials . Clin Infect Dis 2012;54:1699-709.
3. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71.
4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
5. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52:203-8.
6. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7.
7. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit . J Antimicrob Chemother 2008;61: 729-33.
8. Curcio D, Vargas SW, Ugarte Ubiergo S, Varon F, Rojas Suarez J, Paz Chavez C, et al. Tigecycline treatment of critically ill patients: the LatinUser experience. Curr Clin Pharmacol 2011;6:18-25.
9. Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 2007;19:753-4.
10. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Anti-microb Agents 2009;34:101-2.
11. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013;57:1756-62.
12. Sanchez-Romero I, Asensio A, Oteo J, Munoz-Algarra M, Munoz-Algarra M, Isidoro B, et al. Nosocomial outbreak of VIM-1 producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors and outcome. Antimicrob Agents Chemother 2012;56:420-7.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
14. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective multicentre study. Working group on sepsis related problems of the ESICM. Intensive Care Med 1999;25:686-96.
15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. International Sepsis Definitions Conference 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.
17. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70.
18. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak Y, et al. A phase 3, open label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62:29-40.
19. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapene-mase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56:597-700.
20. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbap-enemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012;18:439-48.
21. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimi-crob Agents Chemother 2012;56:2108-13.
22. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50.
23. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51.
24. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther 2012;10:1393-404.
25. Cunha BA. Pharmacokinetic considerations regarding tige-cycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009;47:1613.
26. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetics re-evaluation. J Antimicrob Chemother 2010;65:1311-2.
27. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64.
28. Ariza-Heredia EJ, Patel R, Blumberg EA, Walker RC, Lewis R, Evans J, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis 2012;14:229-36.
29. Tutuncu EE, Kuscu F, Gurbuz Y, Ozturk B, Haykir A, Sencan I. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis 2010;14:224-6.
30. Garcia-Cabrera E, Jimenez-Mejias ME, Gil Navarro MV, Gomez-Gomez MJ, Ortiz-Leyba C, Cordero E, et al. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010;29: 867-71.